Programmed death‐ligand 1 is a promising blood marker for predicting tumor progression and prognosis in patients with gastric cancer

Immune checkpoint inhibitor therapy has been clinically introduced for several malignancies, and its effectiveness has been confirmed by clinical trials. In particular, programmed cell death protein 1 (PD‐1) and programmed death‐ligand 1 (PD‐L1) are widely known as important immune checkpoint molecu...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cancer Sci
Glavni autori: Amatatsu, Masahiko, Arigami, Takaaki, Uenosono, Yoshikazu, Yanagita, Shigehiro, Uchikado, Yasuto, Kijima, Yuko, Kurahara, Hiroshi, Kita, Yoshiaki, Mori, Shinichiro, Sasaki, Ken, Omoto, Itaru, Maemura, Kosei, Ishigami, Sumiya, Natsugoe, Shoji
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2018
Teme:
Original Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5834808/
https://ncbi.nlm.nih.gov/pubmed/29345842
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13508
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items